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Cultivation of Borrelia burgdorferi from Joint Fluid
Three Months After Treatment of Facial Palsy
Due to Lyme Borreliosis
COLLEAGUES - Lyme arthritis is a common manifestation of Lyme
disease in the United States and in Europe [1,2]. Thus far, Borre-
lia burgdorferi has been demonstrated in synovial biopsy speci-
mens [3] and in joint fluid [4], but attempts to isolate and sub-
culture the organism have failed. We report the case of a girl with
Lyme disease, from whom we were able to isolate and propagate
B. burgdorferi from joint fluid and to then perform serological
tests on this isolate.
Casereport. In October 1986, a 15.5-y-old girl was bitten by
a tick in Austria. There was no local skin manifestation, such
as erythema chronicum migrans, and she also never perceived any
generalized symptoms such as malaise, fatigue, headache, mus-
culoskeletal pain, or fever. Her history was free of any relevant
disease.
At the end of January 1987, she was diagnosed with peripheral
paralysis of the left facial nerve. Physical examination was other-
wise normal, and she was afebrile; the patients' body weight was
58 kg. A complete blood count; her erythrocyte sedimentation
rate; and radiographs of paranasal sinuses, mastoid processes,
and petrous pyramids revealed normal findings. Repeated sero-
logical studies (table 1) confirmed the assumed B. burgdorferi
etiology of facial palsy and excluded a viral etiology (i,e., herpes
simplex virus, cytomegalovirus, Epstein-Barr virus, mumps virus,
or coxsackievirus). Oral treatment with amoxicillin-clavulanate
(625 mg, four times per day) was discontinued after 12d because
the patient developed a maculopapular rash. A two-week course
of an oral corticosteroid (1 mg of betamethasone, two times per
day) was prescribed. A lumbar puncture, performed because of
only partial resolution of facial palsy, showed no pathological
findings. Staining and culture attempts for B. burgdorferi in CSF
were negative; the specific antibody titers are listed in table 1.
During treatment with oral doxycycline (100 mg, two times per
day) for two weeks, residual paralysis of the left facial nerve com-
pletely resolved, and the patient remained free of neurological
symptoms.
'IWo months later, the patient developed isolated arthritis of
the right knee without any preceding trauma. A laboratory ex-
amination showed the following: a peripheral leukocyte count
of 7000 cells/rum", with a normal differential; erythrocyte
sedimentation rate, 27 mm/h; normal levelsof creatinine and liver
enzymes in serum; negative rheumatoid factors and antinuclear
antibodies; and normal values for circulating immune complexes
and complement analysis (CH50 and APH50). Using arthrocente-
sis, we collected 60 mL of cloudy joint fluid; microscopic analy-
sis showed two to 11granulocytes per visual field, a test for rheu-
matoid factor was negative, and a culture for B. burgdorferi was
positive. The antibody titers against B. burgdorferi in serum and
joint fluid are included in table 1. Ceftriaxone was administered
intravenously in high doses (4 g per day), in the clinic, over a three-
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day period; thereafter, iv treatment was continued in normal doses
(2 g per day), at the patient's home, for 11d. Response to therapy
was prompt; the patient's gonarthritis completely resolved by the
end of the two-week course of ceftriaxone. The patient has re-
mained healthy during the ll-mo follow-up period; her serum
antibody responses to B. burgdorferi are given in table 1.
Serology (immunoperoxidase slide test). Binding of specific
IgG and IgM antibodies to smears of B. burgdorferi (strain B31
or the patient's isolate [subculture number 2, B2]) on methanol-
fixed slides was visualized by subsequent incubation with
peroxidase-conjugated antibody to human IgG or IgM, followed
by incubation with a chromogenic substrate. In this test the final
titer is defined as the maximal log, dilution of the sera in which
Borrelia are distinctly demonstrable by light microscopy. As
reported previously [5], this method gives identical results to the
immunofluorescence test.
Culture. An aliquot of 0.5 mL of joint fluid from the affected
knee was inoculated into a glass tube containing 5 mL of modi-
fied Kelly's medium (BSK II) [6]. The tube was closed tightly and
incubated at 32 C. Every seven days, the culture was checked for
growth of spirochetes by using dark-field microscopy. After four
weeks, numerous motile spirochetes were detected and could suc-
cessfully be subcultured by the technique mentioned above. The
spirochetes reacted with monoclonal antibodies H 5332(supposed
to be specific for B. burgdorferi [7])and H 9724 (specific for flagel-
lae of Borrelia spp. [8]), as well as with all serum samples con-
taining IgG antibodies against B. burgdorferi strain B31that have
thus far been tested in our laboratory (>20 samples).
Discussion. Optimal antimicrobial therapy for Lyme borre1i-
osis has not yet been defined. In vitro susceptibility tests have
shown that ceftriaxone and erythromycin are more active against
B burgdorferi than are tetracyclines or penicillins [9]. Oral ther-
apy for erythema chronicum migrans, the early manifestation of
Lyme borreliosis, is usually successful with either penicillin,
tetracycline, or erythromycin, although isolated instances of fail-
ure to prevent further disease manifestation have been reported
[1, 10]. Parenteral high-dose treatment has been recommended
for neurological and rheumatologic complications of Lyme bor-
reliosis [1, 11].
This report gives further evidence that oral two-week courses
with amoxicillin-clavulanate or doxycycline,administered in doses
recommended for treatment of primary Lyme borreliosis [1],may
be inadequate for facial palsy due to Lyme disease. Despite clini-
cal resolution of paralysis, subsequent arthritic complication oc-
curred. To our knowledge, this is the first report of the successful
isolation of B. burgdorferi from synovial fluid and the subse-
quent propagation through serial passage. This positive culture
strongly suggests that the spirochetes were not eradicated by the
initial antimicrobial regimens. Lack of meningeal inflammation
could have prevented adequate drug penetration to the site of in-
fection. The potential effect of the concomitant corticosteroid
therapy on the inflammatory process remains speculative. Other
possible explanations of treatment failure, such as insufficient
patient compliance or reinfection by B. burgdorferi,wereexcluded
by close medical and parental supervision. The observed appar-
ent cure of borrelia arthritis by using iv ceftriaxone therapy con-
firms earlier observations [11]. Moreover, the present report in-
dicates that pathogenesis of Lyme arthritis includes not only
immunologic reactions but also directsynovial invasion by B burg-
dorferi, as previously demonstrated by using the silver-impreg-
nation method in synovial biopsy specimens [3].
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Table 1. Symptomatology, treatment, and diagnostic findings of the B. burgdorferi infection.
IgG antibody titers t
Date Symptoms Treatment (no. of days, route)" Specimen B31 B2 Culturef
1/29/87 Facial palsy Amoxicillin-clavulanate (12, po) Serum 1:64 1:128 ND
2/18/87 Facial palsy Betamethasone (14, po) Serum 1:256 1:128 ND
2/25/87 Facial palsy Doxycycline (14, po) CSF <1:2 <1:2 Negative
5/5/87 Gonarthritis Ceftriaxone (14, iv) Serum 1:64 1:64 ND
Joint fluid 1:64 1:64 Positive
6/11/87 None None Serum 1:64 1:256 ND
8/11/87 None None Serum 1:128 1:128 ND
• Po = perorally.
t IgM antibodies were never detected in significant concentration. B. burgdorferi B31
tient's isolate.
t ND = not done.
routine laboratory strain, B2 = pa-
Comparison of the patient's serum IgG antibody titers against
B. burgdorferi B31, the routinely used laboratory strain in Eu-
rope, and B. burgdorferi B2, the isolated pathogen, revealed that
the antibody response to B2 occurred earlier in the course of in-
fection and, therefore, might allow prompter serological diagno-
sis. It is likely that the serologically relevant epitopes of B2 and
B31 are not identical. Further experiments concerning analysis
of the antigenic components in different strains of Borrelia iso-
lated from patients or ticks from the same geographic region,
as well as antigen selection for optimal serological diagnosis of
Lyme borreliosis, are needed [7, 8, 12].
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